RecruitingPhase 1NCT05824585

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Sponsor

Dizal Pharmaceuticals

Enrollment

230 participants

Start Date

May 15, 2023

Study Type

INTERVENTIONAL

Conditions

Lymphoma, Non-Hodgkin

Summary

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial tests DZD8586, an experimental targeted drug, in people with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) — a group of blood cancers that have come back or stopped responding to previous treatments. DZD8586 is designed to block specific proteins that help cancer cells survive and grow. **You may be eligible if...** - You are 18 or older - You have B-cell non-Hodgkin lymphoma confirmed by biopsy that has relapsed or not responded to prior treatment - You are in acceptable health (ECOG 0–2) with stable condition - Your bone marrow and organ function tests are within acceptable limits **You may NOT be eligible if...** - You have unresolved serious side effects from a prior treatment - You have had a prior allogeneic stem cell transplant (from a donor) - You have active brain lymphoma - You are pregnant or breastfeeding - You have a serious infection or uncontrolled illness Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.